Details

Autor(en) / Beteiligte

• Kan, Yuen-Yee
• Liou, Yu-Ligh
• Wang, Huei-Jen
• Chen, Chiao-Ying
• Sung, Li-Chi
• Chang, Chi-Feng
• Liao, Cheng-I

Titel

PAX1 Methylation as a Potential Biomarker for Cervical Cancer Screening

Ist Teil von

• International journal of gynecological cancer, 2014-06, Vol.24 (5), p.928-934

Ort / Verlag

England: by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• OBJECTIVESDNA methylation is a potential biomarker for early cancer detection. Previous studies suggested that the methylations of several genes are promising markers for the detection of cervical intraepithelial neoplasia at grade III or worse (CIN3+). The purpose of the present study was to explore the feasibility of these DNA methylation testing in cervical cancer screening. METHODSA total of 443 women were recruited from the Yuan’s General Hospital. Cervical scrapings were collected for Papanicolaou (Pap) test by using cervical brushes, and the cytological data were used for analysis. The residual cells on the brush were preserved in phosphate-buffered saline solution at 4°C until DNA extraction. Then, the extracted DNA were used for molecular tests, which included human papillomavirus typing and quantification of the methylation levels for PAX1, SOX1, and NKX6-1 genes. Subjects who had abnormal Pap test results underwent colposcopy or biopsy with subsequent conization or major surgery when biopsy results revealed CIN2+. The final diagnosis for this group was confirmed by colposcopy or pathological examination. The study was approved by the institutional review board of Yuan’s General Hospital, and all the molecular tests were performed by ISO17025 certified laboratories. RESULTSThe sensitivity of PAX1 and SOX1 was greater than 80%, and the specificity of PAX1 and NXK6-1 was greater than 80% for the detection of CIN3+ lesions. PAX1 detection alone had a sensitivity and specificity of 86% and 85%, respectively, whereas when used as a cotest with the Pap test, the sensitivity and specificity were 89% and 83%, respectively. CONCLUSIONSPAX1 showed great potential as a biomarker for cervical cancer screening. When incorporating PAX1 detection into current screening protocol, the efficacy of screening could be greatly improved. Moreover, unnecessary referral for colposcopy and biopsy could be reduced up to 60%. However, prospective population-based studies are necessary for further implementation of this screening program.